Synendos Therapeutics Starts Phase 2 Trial in Generalized Anxiety DisorderBASEL, Switzerland, May 20, 2026 (GLOBE NEWSWIRE) -- Synendos Therapeutics (“Synendos”), the clinical-stage biotech company developing breakthrough therapies for neuropsychiatric disorders, announced today that it has started dosing of its Phase 2 efficacy and safety clinical trial in patients with the diagnosis of Generalized Anxiety Disorder (GAD). The study is taking place in collaboration with Professor Allan Young and King’s College, London. This marks the first time a SERI molecule is dosed in a patient population. Preliminary data is anticipated in early 2027.
Synendos Therapeutics Reports Positive and Highly Promising Topline Results from Phase 1 Trials, Paving the Way for Phase 2 in Mental HealthBASEL, Switzerland, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Synendos Therapeutics (“Synendos”), the clinical-stage biotech company developing breakthrough therapies for neuropsychiatric disorders, announced today topline results for its lead asset, SYT-510, a first-in-class inhibitor that modulates a newly identified drug target in the Endocannabinoid System that helps restore healthy brain functions.
